on SPINEWAY (EPA:ALSPW)
Spineway: 2025 Review and Q4 Growth
Spineway, a company specializing in implants for spinal pathologies, announces a 2025 revenue of €12.4 million. This result represents a 4% increase compared to 2024. The last quarter of 2025 was marked by a significant acceleration in sales, reaching €3.8 million, a 34% increase compared to the same period in 2024.
This performance is attributed to several factors, including a postponement of orders expected in the first half of the year, a strengthened presence in Asia and Latin America, and successful geographic diversification. Despite some obstacles, Spineway has maintained steady growth.
For 2026, the company aims for new approvals for its premium ranges, thereby consolidating its position on the international market.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SPINEWAY news